Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
children
critical care
intensive care
pediatric drug therapy
pediatric infectious disease
pharmacology
piperacillin
population pharmacokinetics
renal failure
renal replacement therapy
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
20 12 2022
20 12 2022
Historique:
pubmed:
8
11
2022
medline:
23
12
2022
entrez:
7
11
2022
Statut:
ppublish
Résumé
We aimed to develop a piperacillin population pharmacokinetic (PK) model in critically ill children receiving continuous renal replacement therapy (CRRT) and to optimize dosing regimens. The piperacillin plasma concentration was quantified by high-performance liquid chromatography. Piperacillin PK was investigated using a nonlinear mixed-effect modeling approach. Monte Carlo simulations were performed to compute the optimal scheme of administration according to the target of 100% interdose interval time in which concentration is one to four times above the MIC (100% fT > 1 to 4× MIC). A total of 32 children with a median (interquartile range [IQR]) postnatal age of 2 years (0 to 11), body weight (BW) of 15 kg (6 to 38), and receiving CRRT were included. Concentration-time courses were best described by a one-compartment model with first-order elimination. BW and residual diuresis (
Identifiants
pubmed: 36342152
doi: 10.1128/aac.01135-22
pmc: PMC9764994
doi:
Substances chimiques
Piperacillin
X00B0D5O0E
Anti-Bacterial Agents
0
Piperacillin, Tazobactam Drug Combination
157044-21-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0113522Références
J Antimicrob Chemother. 2016 Apr;71(4):1106-17
pubmed: 26747104
Clin Microbiol Infect. 2022 Sep;28(9):1287.e9-1287.e15
pubmed: 35390523
J Antimicrob Chemother. 2017 Oct 1;72(10):2891-2897
pubmed: 29091190
Int J Antimicrob Agents. 2017 Aug;50(2):227-231
pubmed: 28689876
Nat Rev Microbiol. 2004 Apr;2(4):289-300
pubmed: 15031728
Int J Antimicrob Agents. 2014 Mar;43(3):223-30
pubmed: 24389079
Infect Drug Resist. 2020 Nov 19;13:4155-4166
pubmed: 33244245
J Vis Exp. 2018 Aug 30;(138):
pubmed: 30222156
J Antimicrob Chemother. 2001 Dec;48(6):881-5
pubmed: 11733473
Pharm Res. 2017 Jan;34(1):7-24
pubmed: 27585904
Lancet Infect Dis. 2015 Jan;15(1):46-54
pubmed: 25471555
Clin Pharmacol. 2017 Feb 24;9:39-44
pubmed: 28280397
J Nippon Med Sch. 2013;80(2):119-30
pubmed: 23657065
Curr Opin Pharmacol. 2015 Oct;24:68-78
pubmed: 26667969
Int J Artif Organs. 2017 May 29;40(5):224-229
pubmed: 28525671
Crit Care Med. 2013 Jul;41(7):1761-73
pubmed: 23685639
J Antimicrob Chemother. 1993 Jan;31 Suppl A:39-60
pubmed: 8383655
Acta Anaesthesiol Scand. 2016 Feb;60(2):230-40
pubmed: 26830215
Adv Chronic Kidney Dis. 2017 Jul;24(4):219-227
pubmed: 28778361
Crit Care Med. 2009 Jul;37(7):2203-9
pubmed: 19487937
J Antimicrob Chemother. 2016 Jun;71(6):1651-9
pubmed: 26869692
Clin Pharmacol Ther. 2009 Nov;86(5):479-82
pubmed: 19844225
Clin Infect Dis. 2021 Apr 26;72(8):1369-1378
pubmed: 32150603
Blood Purif. 2012;34(2):138-48
pubmed: 23095413
Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1017-31
pubmed: 20636224
Int J Infect Dis. 2020 Mar;92:133-140
pubmed: 31978581
Antimicrob Agents Chemother. 2015 Sep;59(9):5520-8
pubmed: 26124172
Intensive Care Med. 1997 Aug;23(8):873-7
pubmed: 9310805
Ann Pharmacother. 2018 Oct;52(10):965-973
pubmed: 29730948
Antimicrob Agents Chemother. 2002 May;46(5):1557-60
pubmed: 11959598
Can J Hosp Pharm. 2021 Winter;74(1):21-29
pubmed: 33487651
AAPS J. 2011 Jun;13(2):143-51
pubmed: 21302010
J Antimicrob Chemother. 2013 Mar;68(3):490-1
pubmed: 23152481
Nephrol Ther. 2009 Jun;5(3):218-38
pubmed: 19345175
Pediatr Crit Care Med. 2013 Jul;14(6):e280-8
pubmed: 23823209
J Antimicrob Chemother. 2014 Jan;69(1):180-9
pubmed: 23908259